Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11276 - 11300 of 12702 in total
Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.
Investigational
Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.
Investigational
Matched Description: … It is beneficial in treating patients with diabetic nephropathy. ... is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in
XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B virus (HBV).
Investigational
Matched Description: … developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in
ATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.
Investigational
Matched Description: … In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic …
LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Investigational
rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed and is currently under phase I of the clinical trial.
Investigational
Matched Description: … cancerous growth in several models of human. ... protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in
Resatorvid is an investigational compound designed for the treatment of severe sepsis.
Investigational
PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.
Investigational
Matched Description: … trial in patients with advanced metastatic cancer and lymphoma. ... PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical ... PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express …
Investigational
MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.
Investigational
Investigational
Investigational
PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets. PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically targets the MetAP-2 enzyme. This class of compounds has been shown to prevent both abnormal...
Investigational
Matched Description: … In preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class ... formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in
Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Withdrawn
Matched Description: … Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. ... Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001. …
ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.
Investigational
Matched Description: … combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in
FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
Investigational
Matched Description: … FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in
Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.
Investigational
ADC4022 is an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe asthma.
Investigational
rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide...
Investigational
Matched Description: … protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in
VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor...
Investigational
Matched Description: … VB4-845 is studied in the treatment of certain types of head and neck cancer. …
MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
Investigational
ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington’s disease, Parkinson’s disease and schizophrenia respectively. ACR-16 is a dopamine stabilizer. ACR-16 is also being...
Investigational
Matched Description: … trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington’s ... ACR-16 is also being studied in other psychiatric and neurologic diseases. ... ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled …
NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
Investigational
Matched Description: … NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim ... NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy …
Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Investigational
NS3728 is an orally active chloride channel blocker for the treatment of cancer.
Investigational
Displaying drugs 11276 - 11300 of 12702 in total